For example, in a 2009 pilot evaluation of intravenous glutathione therapy for individuals with Parkinsons disease at the University of South Florida, researchers reported that glutathione IV therapy that mildly benefited motor symptoms was well tolerated and posed no safety concerns. A 2017 case report yielded similar results
For example, one study showed a mean body weight reduction of 20.2% with Tirzepatide over 72 weeks, compared to 13.7% with Semaglutide
Telehealth Security All consultations and prescriptions are handled through a HIPAA-compliant platform to protect patient privacy
Onesizefitsall protocols with no titration or followup
While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved
All medications come from licensed 503A compounding pharmacies and are HSA/FSA eligible